CoChat
Sign Up
Cited by 53Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesChronic Obstructive Pulmonary Disease (COPD) Research

A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results

Haggsträm, Fábio M., Chatkin, José M., Sussenbach-Vaz, Eliana, Cesari, Débora H., Fam, Claudia F., Fritscher, Carlos C.·2006·Pulmonary Pharmacology & Therapeutics
DOI 10.1016/j.pupt.2005.05.003
Open this paper in CoChat — free account

Abstract

Purpose and methods Cognitive behavior therapy (CBT) constitutes the basis of smoking cessation programs. Quitting rates are usually increased by the concomitant use of CBT and pharmacotherapy. There are studies showing the efficacy of bupropion and nortriptyline compared to placebo, but there is just one published comparison between these drugs, unfortunately with low power to detect significant differences. This study was designed to compare the efficacy of bupropion, nortriptyline and placebo in a group of smokers who also received intensive counseling therapy. We conducted a double blind, double-dummy, placebo-controlled trial for smoking cessation that lasted 9 weeks. Patients were randomized to receive nortriptyline 75 mg/day (52 subjects), bupropion 300 mg/day (53 subjects) or placebo (51 subjects). All smokers also received the same intensive cognitive behavior therapy. The target day for quitting smoking was usually day 10. Intensive counseling was provided at baseline, weekly during treatment, and at 10, 13, 16, 20 and 26 weeks. Abstinence was defined as continuous when the subject was not smoking since the target-quitting day (self-report) and had an expired carbon monoxide concentration of 10 ppm or less.Results The sustained abstinence rates at 6 months were 21.6% in the placebo group, 30.8% in the nortriptyline group (p = 0.40), and 41.5% in the bupropion group (p = 0.05). The odds ratio was not statistically different for smokers using nortriptyline or bupropion (OR 1.60; 95% CI 0.66-3.86; p = 0.35). The most common adverse events were dry mouth and drowsiness in the nortriptyline group and dry mouth and insomnia in the bupropion group.Conclusions Treatment with CBT + bupropion resulted in a better 6-month rate of smoking cessation compared to CBT+nortriptyline or CBT + placebo. Abstinence rate in the nortriptyline group was not statistically different from patients in the bupropion or placebo group.

Integrity signals

Registry

Crossref · 10.1016/j.pupt.2005.05.003

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Clonidine has an odds ratio of 1.9 (95% CI 1.3 to 2.7) for abstinence.

    “Clonidine (n=6 studies) ( 102 ) 1.9 (1.3, 2.7) 13% (11 – 22) 22% (17, 30) [14% – 44%]”

    From Tobacco addiction (2008) · cites this paper as [102]

  • Clonidine is observed to be as efficacious as the other medications in promoting cessation.

    “Clonidine is observed to be as efficacious as the other medications in promoting cessation, but the high incidence of side effects may be a deterrent for considering this medication as a primary therapy.”

    From Tobacco addiction (2008) · cites this paper as [102]

  • Meta-analyses of clinical trial results show similar odds ratios, ranging from 1.9 to 3.2, across non-nicotine pharmacotherapies.

    “Meta-analyses conducted for clinical trial results show similar odds ratios, ranging from 1.9 to 3.2, across these non-nicotine pharmacotherapies (see Table 8).”

    From Tobacco addiction (2008) · cites this paper as [102]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Haggsträm, F. M., Chatkin, J. M., Sussenbach-Vaz, E., Cesari, D. H., Fam, C. F., & Fritscher, C. C.
Affiliations
Hospital São Lucas da PUCRS (BR)
Corresponding author
Chatkin, José M.
ORCID
Venue
Pulmonary Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2006-06
Volume
19
Issue
3
Pages
205-209
ISSN
1094-5539 (ISSN-L)
DOI
10.1016/j.pupt.2005.05.003
OpenAlex
W1964076400
Cited by
53
References
21
Citations by year
2025: 2 · 2024: 2 · 2023: 5 · 2021: 4 · 2020: 2 · 2019: 2 · 2018: 2 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 4
FWCI
3.53
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Pulmonary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
smoking cessation, nortriptyline, bupropion, bupropion sustained release, cognitive behavioral therapy, pharmacotherapy, abstinence rates, nicotine dependence, adverse events
MeSH terms
Smoking Prevention, Counseling, Delayed-Action Preparations, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nortriptyline, Sleep Stages, Smoking, Substance Withdrawal Syndrome, Time Factors, Xerostomia, Smoking Cessation, Bupropion, Treatment Outcome, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review